Sho Nambara

1.5k citations
45 papers · 959 indexed · h-index 18
Topics
Cancer-related molecular mechanisms research (10 papers)Gastric Cancer Management and Outcomes (10 papers)MicroRNA in disease regulation (8 papers)
Journals
SHILAP Revista de lepidopterologíaPLoS ONECancer Research
Partner nations
JapanSingapore

In The Last Decade

Sho Nambara

38 papers receiving 952 citations

Peers

Sho Nambara
Comparison fields: 5 of 71
  • Molecular Biology 711
  • Cancer Research 605
  • Oncology 172
  • Pulmonary and Respiratory Medicine 107
  • Immunology 92
Replace Hyung Seok Kim with:
Hyung Seok Kim South Korea
Xin-Ran Tang China
Peng Du China
Taro Tobo Japan
Alexandra Drakaki United States
Qingfeng Ni China
Zhongqiu Lin China
Chenkai Ma Australia
Sho Nambara relative to Hyung Seok Kim South Korea Hyung Seok Kim's profile →
Citations per field
00.5×1.5×1.8×
Hyung Seok Kim · 1×
Citations per year

Countries citing papers authored by Sho Nambara

Since Specialization
Citations

This map shows the geographic impact of Sho Nambara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sho Nambara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sho Nambara more than expected).

Fields of papers citing papers by Sho Nambara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sho Nambara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sho Nambara. The network helps show where Sho Nambara may publish in the future.

Co-authorship network of co-authors of Sho Nambara

This figure shows the co-authorship network connecting the top 25 collaborators of Sho Nambara. A scholar is included among the top collaborators of Sho Nambara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sho Nambara. Sho Nambara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 0
4 0
5 2
6 1
7 5
8 0
9 1
10 1
11 18
12 19
13 39
14 116
15 12
16 5
17 25
18 87
19 25
20 4

About Sho Nambara

Sho Nambara is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology, having authored 45 papers that have together received 959 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (10 papers), Gastric Cancer Management and Outcomes (10 papers) and MicroRNA in disease regulation (8 papers). The work is most often cited by research in Cancer Research (605 citations), Molecular Biology (711 citations) and Oncology (172 citations). Sho Nambara has collaborated with scholars based in Japan and Singapore. Frequent co-authors include Koshi Mimori, Hidetoshi Eguchi, Tomohiro Iguchi, Hidenari Hirata, Takaaki Masuda, K Sugimachi, Hisateru Komatsu, Shuhei Ito, Shotaro Sakimura and Ryutaro Uchi. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026